Premium
Tuberculin anergy mediated by humoral immunity
Author(s) -
Romero Viviana A,
FernandezViña Marcelo,
Encinales Liliana,
Almeciga Ingrid,
Awad Carlos,
Collazos Vilma,
Clavijo Olga P,
Zuñiga Joaquin,
Yunis Edmond J
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.5.a403-b
Subject(s) - immunology , antigen , tuberculin , antibody , tuberculosis , immune system , humoral immunity , delayed hypersensitivity , latent tuberculosis , mycobacterium tuberculosis , medicine , isotype , population , cellular immunity , biology , monoclonal antibody , pathology , environmental health
A small percentage of people infected with M. tuberculosis develop active disease; live bacteria can still be present but are controlled by the host's effective cell mediated immunity (CMI) mediated by MHC class II restricted CD4 + T cells in those that do not develop tuberculosis. Reduction of the CD4 + T cells can produce reactivation of disease in asymptomatic people with latent tuberculosis infection (LTBI). The absence of skin reactivity (delayed type hypersensitivity, DTH) to the Mycobacterium purified protein derivative (PPD) has been described in individuals with active and LTBI; high levels of antibodies to M. tuberculosis glycolipid antigens of the IgM and IgG4 isotype were found in a TB active population with very high prevalence of PPD anergy; we tested the hypothesis that antibodies could interfere with recognition of antigenic determinants blocking the reaction with the immune cell masking the antigen. We will show that anergic LTBI patients have humoral and cellular response to the PPD antigen; in vitro studies showed that in the presence of the patient's autologous serum the proliferation to this antigen was blocked, also that antibodies against HLA alleles or/and antibodies to M. tuberculosis glycolipid antigens mediate anergy (DTH negative, proliferation positive) in individuals with LTBI.